North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $520.9 billion, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care.
Shares of this drug giant have outperformed the broader market over the past year. ABBV has gained 36.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 13.5%. In 2026, ABBV stock is up 29%, surpassing the SPX’s 12.3% returns on a YTD basis.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Zooming in further, ABBV’s outperformance is also apparent compared to the Invesco Pharmaceuticals ETF (PJP). The exchange-traded fund has gained 35.7% over the past year. Moreover, ABBV’s returns on a YTD basis outshine the ETF’s 25.9% gains over the same time frame.
www.barchart.com AbbVie’s strong performance was driven by volume gains and double-digit revenue growth across nine key products, led by SKYRIZI, RINVOQ, and VRAYLAR. Immunology benefited from strong prescription trends and a new Crohn’s disease indication, while neuroscience was bolstered by VRAYLAR, UBRELVY, Qulipta, and the new Parkinson's treatment JUVMO. Moving forward, momentum will be sustained by upcoming label expansions (such as RINVOQ for vitiligo and alopecia areata), pipeline progress in oncology and obesity, and targeted business development like the Apogee Therapeutics acquisition, helping offset modest declines in the aesthetics segment.
On Oct. 30, ABBV shares closed up by 1.4% after reporting its Q3 results. Its adjusted EPS of $3.82 topped Wall Street expectations of $3.74. The company’s revenue was $17.40 billion, surpassing Wall Street forecasts of $17.37 billion. ABBV expects full-year adjusted EPS in the range of $13.95 to $13.99.
For the current fiscal year, ending in December, analysts expect ABBV’s EPS to grow 39.9% to $13.99 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 31 analysts covering ABBV stock, the consensus is a “Strong Buy.” That’s based on 22 “Strong Buy” ratings, two “Moderate Buys,” and seven “Holds.”
www.barchart.com This configuration is more bullish than three months ago, with 21 analysts suggesting a “Strong Buy.”
On Nov. 4, Freedom Broker kept a “Buy” rating on ABBV and raised the price target to $315, implying a potential upside of 6.8% from current levels.
The mean price target of $302.37 represents a 2.6% premium to ABBV’s current price levels. The Street-high price target of $350 suggests an upside potential of 18.7%.
On the date of publication, Neha Panjwani did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
‘I Think That the Goal of the Bears Out There Is to Derail the Anthropic IPO’: Jim Cramer Warns as Amazon and Alphabet Slide KeyBanc Just Downgraded Vistra Stock. Here's Why. Short Straddle Screener Results for November 5th Nasdaq Futures Slip as Chip Selloff Rages On; Earnings and Fed Speak on Tap